The authors indicate that GD3 synthase contributes to gefitinib resistance in epidermal growth factor receptor-positive breast cancer cells, and is a potentially useful therapeutic target in drug-resistant breast cancers.
[Glycoconjugate Journal]
6445212
AAAAAAAA
items
1
apa
0
default
asc
1
172812
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
